Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742193 | 1.00 | MAPT (0.38) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30051424 | 0.83 | MAPT (0.44) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20189764 | 0.83 | MAPT (0.44) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29742367 | 0.80 | — | — | |
| SCHEMBL20189905 | 0.80 | — | — | |
| SCHEMBL16702653 | 0.78 | MAPT (0.58) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29742351 | 0.74 | MAPT (0.44) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20189974 | 0.74 | MAPT (0.44) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25244770 | 0.71 | MAPT (0.59) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16702512 | 0.71 | MAPT (0.40) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110198934-B | Pyrimidine carboxamides as GSK-3 inhibitors | 百时美施贵宝公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3544968-B1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3544968-B1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3544968-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098413-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098413-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | MAPT 301/4885ALDH1A1 3670/4885CYP1A2 1718/4885 |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MAPT 301/4885ALDH1A1 3670/4885CYP1A2 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.